Tetanus Toxoid Vaccine Market Size (2024 - 2029)

Tetanus Toxoid Vaccine Market Analysis

The Tetanus Toxoid Vaccine Market size is estimated at USD 12.05 billion in 2024, and is expected to reach USD 17.19 billion by 2029, growing at a CAGR of 5.05% during the forecast period (2024-2029).

Factors such as increasing cases of tetanus and diphtheria, rising research activities for developing novel vaccines, and government initiatives for vaccination are anticipated to contribute to the market growth during the forecast period.

Tetanus, commonly called lockjaw, is a severe, non-contagious illness. It is caused by a bacterial toxin that disrupts the nervous system, resulting in painful muscle spasms, especially in the jaw and neck. The huge burden of tetanus and diphtheria cases is likely to fuel the demand for vaccines to propel the market growth. For instance, according to the data published by the World Health Organization in October 2023, 538 cases of diphtheria were reported in Guinea in 2023. Similarly, according to the data published by the World Health Organization in August 2023, 5,898 cases of diphtheria were reported in Nigeria in 2023. Thus, the significant prevalence of diphtheria is anticipated to drive the need for tetanus toxoid vaccines, contributing to market growth.

Also, government initiatives to ensure vaccination among the population are likely to drive market growth. For instance, in August 2023, according to the World Health Organization recommendation, an individual undergoes a vaccination regimen consisting of six tetanus-toxoid-containing vaccines (TTCV) doses, comprising three primary doses and three subsequent booster doses. Additionally, in August 2022, the Public Health and Family Welfare Minister of Madhya Pradesh, India, launched the state-level DPT/TD vaccination campaign program at the Kamala Nehru Girls School Auditorium, Bhopal. Thus, such initiatives are anticipated to drive the demand for tetanus toxoid vaccine and boost the market growth.

Moreover, product launches and collaborations to develop tetanus vaccination and immunization are other driving factors of the tetanus toxoid vaccine market. For instance, in August 2022, IBSS Biomed SA funded a clinical investigation to evaluate the immunogenic and safety profile of a booster immunization with tetanus and diphtheria bivalent vaccine CLODIVAC (developed by IBSS Biomed SA) and Td-Impfstoff Mérieux (produced by Sanofi Pasteur) in healthy adult populations. Thus, market player efforts to boost research and development for novel vaccines are expected to drive market growth.

Therefore, the above-mentioned factors, such as the high burden of tetanus and diphtheria cases, rising government initiatives and programs, and market player efforts, are expected to drive the market growth of the tetanus toxoid vaccine. However, the side effects associated with the toxoid vaccine restrain the market growth during the forecast period.

Tetanus Toxoid Vaccine Industry Overview

As per the scope of the report, the tetanus vaccine, also known as tetanus toxoid, is a toxoid vaccine used to prevent tetanus. Five doses are recommended during childhood, with a sixth given during adolescence. After three doses, almost everyone is initially immune, but additional doses every 10 years are recommended to maintain immunity.

The tetanus toxoid vaccine market is segmented by vaccine type, end user, and geography. By vaccine type, the market is segmented into diphtheria, tetanus, and pertussis (DTaP), diphtheria and tetanus (DT), tetanus, diphtheria, and pertussis (Tdap), and other vaccines. By end user, the market is segmented into hospitals and clinics and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.